Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Bioequivalence of BR2008 vs BR2008-1 in Healthy Volunteers
NCT05068193Phase 1Completed
- Sponsor
- Boryung
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BR2008 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration and Maximum Plasma Concentration. Started Sep 2021; status: completed.
02
Drugs
BR2008
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05068193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068193.